<SEC-DOCUMENT>0001178913-21-003293.txt : 20211028
<SEC-HEADER>0001178913-21-003293.hdr.sgml : 20211028
<ACCEPTANCE-DATETIME>20211028083022
ACCESSION NUMBER:		0001178913-21-003293
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211028
FILED AS OF DATE:		20211028
DATE AS OF CHANGE:		20211028

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		211355169

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2126709.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of October 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-38556</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">ENTERA BIO LTD.</div>
      <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in Its Charter)</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Hadassah<br>
        Minrav Building &#8211; Fifth Floor</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Jerusalem, Israel</font><br>
        (Address of principal executive office)</div>
      <div style="text-align: center; line-height: 1.25;">_____________________</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746; &#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;"><u>CONTENTS</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K of the registrant consists of a press release issued by the registrant on October 28, 2021, attached hereto
          as an exhibit and incorporated by reference herein.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K and Exhibit 99.1 hereto shall be deemed to be incorporated by reference into the registration statements on
          Form F-3 (Registration Number: 333-238988) and Form F-3 (Registration Number: 333-239843) of Entera Bio Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently
          filed or furnished.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;"><u>Exhibit</u></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zd784ab02abcc452d8a1dc569e301f522" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit
                  99.1:</a></div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Press
                  release dated October 28, 2021.</a></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>SIGNATURES</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z731ab6e3b90f4ebbb161f732733b0564" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ENTERA BIO LTD.</div>
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">(Registrant)</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 24%; vertical-align: top;">&#160;</td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 24%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">/s/ Spiros Jamas, Sc.D</div>
            </td>
            <td style="width: 23%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td nowrap="nowrap" style="width: 24%; vertical-align: bottom;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Name: Spiros Jamas, Sc.D</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 24%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Title: Chief Executive Officer and Director</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 24%; vertical-align: top;">&#160;</td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="line-height: 1.25;">Date: October 28, 2021</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1<br>
        </font></u></div>
    <div><u><font style="font-weight: bold;"> </font></u>
      <div id="DSPFPageHeader">
        <div style="line-height: 1.25;"><img width="101" height="57" src="image0.jpg"></div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Entera Bio Publishes Key Study Describing its Oral Delivery Technology </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Platform for Biologic Drugs</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">&#8210;Study describes a dual mechanism of action approach to oral drug delivery of large molecules, </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">the &#8220;Holy Grail&#8221; of drug development.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="line-height: 1.25; font-style: italic; text-align: center;">&#8210;Technology is utilized in Entera&#8217;s EB613 oral PTH drug for osteoporosis and several </div>
      <div style="line-height: 1.25; font-style: italic; text-align: center;">other molecules now in development by Entera and in collaboration with pharmaceutical companies.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">BOSTON, Massachusetts &amp; JERUSALEM, Israel &#8211; October 28</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup><font style="font-weight: bold;">,</font><font style="font-weight: bold;"> 2021 </font>&#8211; Entera Bio Ltd. (NASDAQ: ENTX), today announced that researchers at the company and the University of East Anglia in the UK published preclinical in vivo studies which demonstrate the technologies
        efficiency in the oral delivery of large molecule biologic drugs. The approach described in the research underpins Entera&#8217;s lead product, EB613, an oral parathyroid hormone (hPTH) entering Phase 3 clinical development for the treatment of
        osteoporosis. The pivotal Phase 3 study is planned for 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">The studies were published on line in the peer-reviewed <font style="font-style: italic;">International Journal of Pharmaceutics X</font>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Entera&#8217;s highly innovative technology has the potential to transform the way we treat many diseases,&#8221; stated William Fraser, MD, Professor of Medicine at The Norfolk and Norwich University
        Hospitals and Norwich Medical School at the University of East Anglia. &#8220;Not only can replacing injections improve patient compliance and reduce patient discomfort, but the administration of oral PTH in both hypoparathyroidism and osteoporosis will
        allow for the customized titration of dose so critical to each individual patient. At present, most injections are administered via &#8220;pen&#8221; injectors, which are frequently not amenable to dose titration&#8221;.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#8220;Entera&#8217;s innovation is to combine in a single formulation two approaches to enhancing the delivery of large molecule biologics,&#8221; said Spiros Jamas, the company&#8217;s CEO. &#8220;This research supports our
        strategy to address the two key challenges in delivering hPTH to the bloodstream at appropriate therapeutic levels consistently:&#160; protecting proteins from breaking down in the gastrointestinal tract; and 2) improving absorption of proteins through
        the gastro-intestinal tract.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#8220;With a burgeoning number of injectable biologics on the market and in development, there is a growing need for effective oral formulations especially in chronic conditions where replacing
        injections with oral dosage may result in higher patient compliance, adherence, and quality of life,&#8221; stated Entera CEO Spiros Jamas.&#160; &#8220;Beyond the near-term opportunity for our EB613 oral PTH in osteoporosis, Entera&#8217;s platform technology has
        applications in many other indications currently treated through injectables.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">In this paper researchers evaluated three different formulations of oral hPTH (1-34): 1. hPTH with a protease inhibitor which can protect the molecule in the gastrointestinal tract, and 2. hPTH
        with just a permeation enhancer (SNAC) which allows for the trans-cellular absorption of large molecules in the GI tract, and 3. hPTH combined with both protease inhibitor and permeation enhancer (the formulation technology currently utilized by
        Entera). In studies utilizing a porcine model, the Entera combined formulation achieved significantly higher PTH blood levels (Cmax and AUC, ~10- and&#160;~20-fold respectively) as compared to each of these approaches on their own. The researchers
        concluded that an appropriate combination of these different technological approaches considerably contributes to the efficient oral delivery of a number of biological macromolecules.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">The study is titled, &#8220;The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin
        inhibitor, and teriparatide study in pigs.&#8221; The authors on the paper are, Gregory Burshtein, Constantin Itin, Hillel Galitzer and Phillip Schwartz, from Entera Bio, Jonathan C. W. Tang, of the University of East Anglia (Norwich, UK) William D.
        Fraser, of the University of East Anglia and Norfolk and Norwich University Hospital (Norwich, UK).</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Entera Bio</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to
        cost, convenience and compliance challenges for patients. The Company&#8217;s proprietary, oral drug delivery technology is designed to address the technical challenges of negligible bioavailability and high absorption variability through the utilization
        of an approved synthetic absorption enhancer to facilitate the absorption of large molecules, and combined chemical and biological protection from enzymatic degradation in the GI tract. Entera is constantly working on the development and
        optimization of its delivery platform to enable oral delivery of a wider range of biologic molecules The Company&#8217;s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in
        clinical development. The Company recently completed the Phase 2 study for EB613. Additionally, Entera&#160; licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration
        with Amgen Inc. For more information on Entera Bio, visit <u>www.enterabio.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Various statements in this release are &#8220;forward-looking statements&#8221; under the securities laws. Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221;
        &#8220;design,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;likely,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and &#8220;would,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements.
        Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be
        accurate indications of when such performance or results will be achieved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Important factors that could cause actual results to differ materially from those reflected in Entera&#8217;s forward-looking statements include, among others: changes in our interpretation of the
        complete 3-month biomarker data from the recently completed Phase 2 clinical trial of EB613, the timing of data readouts from the recently completed Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, and our
        analysis of those full results, the FDA&#8217;s interpretation and review of our results from and analysis of our Phase 2 trial of&#160; EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our
        ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the impact of COVID-19 on Entera&#8217;s business operations; the potential disruption and delay of manufacturing supply chains, loss of available
        workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay-offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that
        Entera is contractually obligated to provide, such as those pursuant to Entera&#8217;s agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of
        COVID-19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United
        States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the recently completed&#160; Phase 2
        clinical trial of EB613; the size and growth of the potential market for EB613 and Entera&#8217;s other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation;
        the scope, progress and costs of developing Entera&#8217;s product candidates including EB612 and GLP-2; Entera&#8217;s reliance on third parties to conduct its clinical trials; Entera&#8217;s expectations regarding licensing, business transactions and strategic
        collaborations; Entera&#8217;s operation as a development stage company with limited operating history; Entera&#8217;s ability to continue as a going concern absent access to sources of liquidity; Entera&#8217;s expectations regarding its expenses, revenue, cash
        resources, liquidity and financial condition; Entera&#8217;s ability to raise additional capital; Entera&#8217;s interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera&#8217;s ability to obtain and
        maintain regulatory approval for any of its product candidates; Entera&#8217;s ability to comply with Nasdaq&#8217;s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States;
        Entera&#8217;s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the &#8220;Special Note Regarding Forward-Looking Statements,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis
        of Financial Condition and Results of Operations&#8221; sections of Entera&#8217;s annual and current filings which are on file with the SEC and available free of charge on the SEC&#8217;s website at http://www.sec.gov. Additional factors may be set forth in those
        sections of Entera&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera&#8217;s annual report on Form 20-F and current reports on Form
        6-K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera&#8217;s results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially
        realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">All written and verbal forward-looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or
        referred to herein. Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera
        undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Spiros Jamas, CEO</div>
      <div style="line-height: 1.25;">Tel: +001 617-362-3579</div>
      <div style="line-height: 1.25;"><u>spiros@enterabio.com</u></div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !- (@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH ***1F"@DD #DD]J %JG>ZI9Z<46YG59)#B.)06>0_[*CD_A7'W/C&]\1Z
MO)HG@\(WE_\ 'UJLB[HH!_L#^)O3M_.NET;P_::.K2*TES>R#]]>7#;Y93[G
ML/88 K5T^1>_]QFI\S]W[S0MIY9UWO;M"I^Z'(W?B!T_.IZ**R- HHHH ***
M* "BBB@ HHHH **** "BBB@ KR#XO>,IH7_X1K3Y"A9 UXZG!(/2/\>I^H%>
MOU\Y>.]'NSX\U:XEEAA@:8.L\K@+C P!W)'3 ]*ZL(Z:J<U1[')C)RC3M'J>
MV^#/#L'AGPS:642CS6023N!R\A'/Y=!["MJXNH+5-]Q-'$OJ[ 5RWA[6KCQ=
MIB3V.I6\$*?NY1$N90P'.0WW<]1Q6S#X<T]'\V:-[J;_ )Z7#%S^O%<52I5E
M)^[KYZ?AO^1M!^ZN1:%>7Q79EBEE#<7C_P#3&,X_.H&U#Q)=_P#'MI<=NIZ&
M9LFNBCC2)=L:*JCH%&!3ZR=*I+XI_=I_F/ED]V<HVG>*KGF34HHL]D./Y"J\
MGAK7V&3JH<^\KBNSHJ'@X/=M_-B=&+W;//+FP\1Z:IE,MRR#J\4I8#\*?IOB
M^]MI%6\(N(<\DC#@>H/>N_->=>*;*.#7C';(,S*K;%'\1)'ZUQ8BC/#)5*4G
MZ&-2#I^]%GH<4BRQ+(C;D<!E/J#3ZK:?;FUTZWMV.6CC53]0*LUZ\6VE<ZEL
M%%%%,84444 %0S7"QG:JM)(>B+U_^M^-34U450< #/7WI._0"D;2>[_X^IBD
M?_/&%B ?]YNI_#%8WBCP'I'B?3H[>6(6TT.?(GA4!DSV([CV-=113I_NY<\=
M^Y$H1DK-7/ Y/A]XX\(Z@;S1)#/MX$MF^"P]&1NOTYK=L_B?XJTT"+7/"\\I
M7@R1Q/$Q_#!'\J]?HKKEBN=?O(I_@8+#<G\.31YQ;_&#3I.)=#UA&[A80W]:
MTHOB/%=<6GAKQ#.3Z6>!^9-=K163G2Z1_$T4*G67X',1:[XCO1_HWA22!3_'
M?7B1X_X"NXU=BM=>N<&]U&VME[QV4.3_ -]OG_T$5M5'+,D*;FS[ #))] *A
MS2V27]>9?)W95*6NEVSW,TCD(N6EE<LQ_/\ D*R-(TR6]U)];OXRCN<V\+=4
M7L3[XK4%D]Y.L]Z!MC.Z*WSE5/\ >;U;]!6C7-*#JR4I;+;_ #%RW>NR"BBB
MMC0**** "L^?7M'MIW@GU6RBF0X:.2X167Z@GBM"O#/B3]CU+XI:;I[^1#&@
MB2XE;"CYFW$L?]W'6MZ%)59<K,:]1TXW1Z]_PDV@?]!O3O\ P*3_ !K31UD1
M71@R,,JP.01ZUREW%X0\3M)H""TN6DB\Y_L@7Y55A_&OW><<5A1_$:ZT_P 7
M'PY>Z;96\%KGSKA+DE(HU3=GE1VQQZT*BY+W5K^@>U4?B>AZ517F-Y\5;RU\
M0Z?:-H$L5C>LOE/.^V61&;:'"]OH:R/'&O>);GQY9>'K2Y%IN956.VN& D#-
MD%S@$' Z#.,U4<+-NSTZDRQ,$KK4]EHKD]0\73:'':V>H6D4VMW<FRVL+*4M
MN'0%F8#:.N21^=9C^.M6TWQK8^'M8TJU7[:%\N2TG9RNXD#.0,\@YZ>M9JA-
MJZ+=:"W._HKS8_$N]M?&4F@ZCI]G!' Q-Q=)<EEC0+N+<J.<8X]:T-.\>75[
M?7-U=:1+IOAZ"!IOM]X&5I.<+M&,<^G)IO#U%JT)5X/9G<TFU=V[ W8QFN-?
MQ9K5SH$VO:?I%M'IL<;3(;VX*22QCG<%"D+G' )YJ3P+XQN/%NE7FH7%BEI%
M!)L7;(6W87)Z@=,BE*C)1<GLBE5BY*/<Z9K^RC<H]W K*<%3( 14L5Q#.NZ&
M5) .Z,#7GND-I5Q>7UUJ[1[6.Y%?.222<C%:?A>PE35)[^..2WL"K",/U<9X
M_+UKRJ6,E.2LE9^>J\V9QK.36FYU"ZG9/?&R6X4W(ZQCJ.,U;KEM#O[.]OKV
M^^PQ6_E L]QO))R?\!4H\17M\9&TK33/!&<&61]N[Z"MH8J+CS2>^UKEJHK7
M9TE%8V@Z\FLK(IB,4T6-RYR"/445O3J1J1YH[&D9*2NC7=TC4L[!5'4DX KQ
M'PE-:^(/C%JFJW$D)MXO-=/-88(X1>O7CFO:+RQM=1M6MKRWCN('QNCD7<IQ
MR.*R_P#A#?#/_0!T[_P'7_"NNC5C",D]WH8U:<IRBULB);WPY9^)X8(! -4O
M(" T*Y_=)EOF(X Z_6O+? FEV_C'XB:OK%ZOFV\$K3JA^Z[,QV ^H &<>PKU
MZS\-:'I\QFL])LX)"I0O'"JDJ>HR.U6-/T?3=)60:=8V]J)""XAC"[L=,XIQ
MK*$9*-[M6N*5%SDG*UD>1:A)'KOQ[MXG=?)LG5?F/&8UW8_[Z-)H4T6K?'34
M;V[D2-;5I=@D;'W (QU_.O57\+Z#+=F[DT>R:X9_,,IA4L6SG.?7--N_"GA^
M^OOMMUH]E-<DY,KQ DGU/K6GUF%K6Z6,_J\KWOUN>0R7<_\ PNV]DN]2BTZ5
M7>.WN+B(.BKMPF 2!R.ASWKN]+L_#&G>)DO+K6UU?Q#<G:DKNKL@Q_"B<(N,
M\G\ZZC4_#FBZRZOJ6EVMTZ#"M+&"0/3/I4EEHNEZ; T%CI]K;1N,,L407</?
M'6IGB(RBDM-+%0H2BV]];GCG@'3;?QA\0]8UF]3S;>"5ID0\JS,QV9]0 ,X]
MA6G\:M1E-QH^CM(8[.4F:8]C@A1GZ#)_&O4M.T?3=)61=.L;>U$A!<0QA=V.
MF<4W4]$TS6HTCU.PM[M8SN03(&VGVI_65[93MHMA?5VJ3A?5GE_Q \5QW7A!
M[+P^X.DQF.VFO ,)(>T4?KP,L1P,8[UL>#432?A%&Z.IDN%=VP<X9VP/TQ7;
MW&A:3=6<-G/IMK):PG,<+1 HGT'046^AZ5:6K6MMIUM%;L^]HTC 4MZX]:QK
MU%/#NE#1E*C/G<V^ECDM(;0H]!?^T6A>=V8[<9<#H /2DT2\NK?0=4E9G-JL
M>V+<>C'C _.NP_L;3!_RX6__ '[%6'M+>6#R'@C:'^X5&W\J\B.#FK:I65M/
MU&J+5O(X!89(/!+RH#BXN1O(_NC@?J*W-/UK3M-\+PE9D,RQ_P"J!^8N?;ZU
MTB6T"6_V=84$.,>6%^7'TJM%HVFPR^9'8P*XZ$(*J&%J4VG!K:PU2E%Z=C'\
D'Z9+:V\U[<*5DN,;5(Y"^OXFBNFHKKHTE2@H+H:PBHQLC__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
